With more than 26,000 active members, ERA is one of the biggest nephrology associations worldwide and one of the most important European med. associations.
💥Save the date! We are honored to announce the Nephrology Pearls session at
#ERA22
, chaired by Serhan Tuglular and Christoph Wanner, happening on:
📅 May 22, 11:15-12:45 (CEST)
Discover our Scientific Programme 👉
📣 Save the date! Symposium 7.1 at
#ERA22
will focus on
“Heart and Kidney: an insidious relationship”, join our speakers on
📅 May 20, 08:00-09:30 (CEST)
Discover our Scientific Programme 👉
📣 Save the date! Symposium 4.1 at
#ERA22
will focus on
“Renal and cardiac protection in diabetic and non-diabetic CKD”, join our speakers on
📅 May 20, 08:00-09:30 (CEST)
Discover our Scientific Programme 👉
💥Save the date! We are honored to announce Valerie Luyckx’s Welcome Lecture at
#ERA22
, “Equity, sustainability, and ethics in kidney health” happening on:
📅 May 19, 17:00-18:15 (CEST)
Discover our Scientific Programme 👉
📣 Save the date! Symposium 0.1 at
#ERA22
will focus on
“Late Breaking Clinical Trials”, join our speakers on
📅 May 20, 11:45-13:15 (CEST)
Discover our Scientific Programme 👉
📣 Save the date! Symposium 5.7 at
#ERA22
will focus on
“The CONNECT project: Cognitive decline in Nephro-Neurology: European Cooperative Target”, join our speakers on
📅 May 21, 11:45-13:15 (CEST)
Discover our Scientific Programme 👉
💥Save the date! We are honored to announce Kevin Tracey’s Plenary Lecture at
#ERA22
, “Bioelectronic Medicine, hypertension and inflammation” happening on:
📅 May 21, 10:45-11:30 (CEST)
Discover our Scientific Programme 👉
💥Save the date! We are honored to announce the Awardees’s Plenary Lecture at
#ERA22
, chaired by Orsolya Cseprekál and Christoph Wanner, happening on:
📅 May 22, 10:15-11:00 (CEST)
Discover our Scientific Programme 👉
📣 Save the date! Symposium 3.3 at
#ERA22
will focus on
“New avenues in lupus nephritis”, join our speakers on
📅 May 21, 15:00-16:30 (CEST)
Discover our Scientific Programme 👉
📣 Save the date! Symposium 0.8 at
#ERA22
will focus on
“CKD in Europe, the voice of the patients”, join our speakers on
📅 May 21, 08:00-09:30 (CEST)
Discover our Scientific Programme 👉
📣 Save the date! Symposium 4.2 at
#ERA22
will focus on
“Cachexia or Protein Energy Wasting: what is new in CKD?”, join our speakers on
📅 May 21, 11:45-13:15 (CEST)
Discover our Scientific Programme 👉
💥Save the date! We are honored to announce Catherine Boileau’s Plenary Lecture at
#ERA22
, “PCSK9: a journey of discovery from genetics to clinical trials” happening on:
📅 May 20, 10:45-11:30 (CEST)
Discover our Scientific Programme 👉
📣 Save the date! Symposium 8.2 at
#ERA22
will focus on
“AKI-CKD transition - is it inevitable?”, join our speakers on
📅 May 21, 17:00-18:30 (CEST)
Discover our Scientific Programme 👉
📣 Save the date! Symposium 8.1 at
#ERA22
will focus on
“Upcoming innovations in acute kidney injury”, join our speakers on
📅 May 20, 17:00-18:30 (CEST)
Discover our Scientific Programme 👉
💥We are happy to announce the nomination of the new ERA President: Roser Torra from Spain.
🎉Congratulations! We are looking forward to working together for the future of the ERA Family.
💯Exitos!
@torra_roser
📣 Save the date! Symposium 0.4 at
#ERA22
will focus on
“2021 Pearls NDT and CKJ”, join our speakers on
📅 May 20, 08:00-09:30 (CEST)
Discover our Scientific Programme 👉
🌟 Exciting news for the ERA Community! Roser Torra - Chief of clinical nephrology at
@FPuigvert
- begins her term as President of ERA.
With her vision and leadership, we're filled with hope for a bright future.
¡Buena suerte!
@torra_roser
🎉We are very happy to announce that the newly elected CKJ Editor-in-Chief is Maria José Soler Romeo. She will start her term as CKJ Editor-in-Chief in June 2022 and will serve the journal for 3 years. Congratulations🎉!
@CKJsocial
@PepaSolerR
We have changed our name after a vote with our members 😍 we will now be The European Renal Association - ERA. It is simple and straightforward. A new era for ERA 😄
📣 Save the date! Symposium 0.2 at
#ERA22
will focus on
the ERA Registry, join our speakers on
📅 May 20, 08:00-09:30 (CEST)
Discover our Scientific Programme 👉
🚨Huge late-breaking trial alert - NefIgArd🚨
Nefecon is approved for IgA by the FDA & EMA based on proteinuria data, but now see the long-awaited eGFR slope data!
#ERA23
Spoiler alert - the drug works better than placebo
Thread below 🧵👇
By
@jamiekwillows
ASN Highlights: Lupus nephritis
LUNAR post-hoc: with adequate B cell depletion with Rituximab more likely to achieve complete remission.
NOBILITY trial: Obinutuzumab+MMF vs. placebo+MMF
💥96% B cell depletion by week 2
💥>50% renal response at weeks 52 and 76
#eraedta20
‼️Management of Primary GN‼️
#Membranous
⭐️3 recent trials
⭐️Rituximab: 65% remission at 1
year
⭐️Ponticelli: 85% remission at 1 year
No direct comparison of rituximab v Ponticelli
Is there an optimal combination of rituximab, cyclophosphamide & steroid?
#ERA23
#minimalchange
#fsgs
#podocytopathy
⭐️Minimal change = podocyte
DAMAGE
⭐️FSGS = podocyte LOSS
⭐️ FSGS is obsolete term
⭐️ Instead define by the cause
eg genetic, viral, drug related
#ERA23
🎉We are thrilled to announce and congratulate the newly elected Ordinary Council Members:
👏Kitty Jager, The Netherlands
👏Jennifer Lees, United Kingdom
👏Siren Sezer, Türkiye
🌟We look forward to the innovative ideas and dedication they will undoubtedly bring to their new roles
🔍Check out one of the best NDT articles of the past years 👇
📌Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion"
#ERA60years
#BestOfNDT
📢NEW in CKJ!
Management of posttransplant diabetes mellitus: an opportunity for novel therapeutics
📸Pathophysiology of PTDM
📸Summary of renal, cardiovascular & metabolic actions of GLP-1 RA, DPP4i & SLGLT2i
📖
@PepaSolerR
@nuria_montero_p
@crz_garrit
COL4A3 and COL4A4 pathogenic variants in the normal population: redefining Alport syndrome?
By Judy Savige
✏️
@drvt87
#ERA24
#SoMe
team
💥Time to change from Alport syndrome to Alport spectrum!!
⚡️ XL- kidney failure in males and 20% of females by the age of 60
⚡️ AR-kidney
Dr Emily McQuarrie
@mcq_emily
- invited speaker of
@ynptweets
@ERAEDTA
Biopsy practice varies widely!
💉More biopsies = more GN
💊Safe to continue aspirin
‼️Risk of thrombosis x3 in ~10 days if aspirin stopped
❌No evidence for bleeding times/DDAVP
@scotrenalbiopsy
#eraedta20
⚡NDT Digest:
👉Thrombotic microangiopathy and their mimickers
📸Disease entities that may mimic a TMA on the kidney biopsy
📖Read more in our journal NDT:
@NDTsocial
@SethiRenalPath
First foray into establishing a European advocacy group for Women in Nephrology😊
Considering how to tackle
⭐️Inclusivity
⭐️Mentorship
⭐️Workshops
⭐️Trial Representation
⭐️Imposter Syndrome
⭐️Language - it matters
⭐️Micro aggression
#ERA23
#goingdowninhistory
The new ERA-EDTA Council Members are Maria Jose Soler Romeo (Spain), Kate Stevens (United Kingdom) and Christoph Wanner (Germany). Congratulations!
#ERAEDTA18
#councilelections
#nephrology
Ready for the
#ERAEDTA21
late-breaking clinical trial session ? Here we go !
🔥 Avacopan in C3G
🔥 Iptacopan in IgAN
🔥 Dapagliflozin in FSGS
🔥 LUST in ESRD patients at high CV risk
NEW! Promotional Registration open for the 1st Kidney Meets Liver Meeting in Amsterdam on 16th March 2018! Register within 28th February to take advantage of the reduced fee.
#KML2018
#Nephrology
#Hepathology
#NAFLD
🚨 Short recap of all 7
#ERA23
Late Breaking Clinical Trials 👇
📍Runcaciguat ph2
📍NEFIGARD
📍Niclosamide in COVID
📍Osocimab (fact XI inhibition in ESKD)
📍CONVINCE
📍Atacicept in IgAN ph2b
📍DiaTT
Covered by
@nephroseeker
@jamiekwillows
🔗
Simultaneous publication in
@JASN_News
during Efficacy and safety of avenciguat in diabetic and non-diabetic kidney disease: Pooled analysis from two Phase II randomized controlled clinical trials
✍️By
@HeerspinkHiddo
🎨Simultaneous visual abstract publication (by
Last
#ERA23
day, Eduard Fu at his best talking about improving outcomes with the help of big data.
Don’t worry it’s about numbers, but more about the message and methods
Do you here it,
@NephJC
?
Management of dialysis patients during the current
#coronavirus
outbreak. ERA-EDTA shares the Milano experience on coronavirus management in dialysis centers, which provide clear and efficient instructions for each possible scenario.
Read it here
#COVID19
Prof Knauf: Disorders of Potassium how many bananas do you need to eat to raise your potassium to 10mmol - assuming no K excretion?
6 only 🍌🍌🍌🍌🍌🍌
#ERAEDTA19
@ynptweets
Katherine Tuttle with a practical overview
#ERA24
📍 Half of CKD cases are attributable to diabetes
📍10% of patients with CKD survive to reach kidney failure
📍90% people with diabetic kidney disease die, mainly because of heart failure or atherosclerotic and CV events
Incremental dialysis helps to maintain Residual Renal function in HD and PD patients and it could be a key predictor of survival. Tips and type of patients who could benefit! Nice talk by
@EnricVilar
in
#eraedta2020
#virtual
#fromhome
#ERA22
is the official Congress #
This year we will try to make it easier to find different talks/tweets by introducing a series of additional # for different topics. Please see photo & try to use them alongside
#ERA22
e.g For LBCT related tweets use
#LBCT22era22
#ERA22
In memory of
#TinaTurner
. A wonderful, legendary woman.
Thank you for your incredible support and contribution in raising awareness on kidney health.
You will always be a source of inspiration for future generations. ❤️
#ShowYourKidneysLove
@EKHA_EU
📣 The April issue of CKJ is now online!
👉
Selected paper:
➡️Thrombotic microangiopathies assessment: mind the complement
📖
📸TMA management algorithm
@CKJsocial
NDT Review:
Hematological disorders following kidney transplantation
📸Potential causes of post-transplant cytopenia in kidney transplant recipients
📸Graphical presentation of mode of action for novel drugs and overview of their use in renal impairment
📖
🔴Live in Rome (Italy) for the
@goKDIGO
controversies conference on maintaining
#kidney
health and preventing CKD!
🌟 ERA & KDIGO are committed towards primary prevention of
#CKD
💪
🤝 Let's make strides towards a healthier future together!
#KDIGO
#CKDPrevention
Circulating Anti-Nephrin antibodies in post-transplant recurrent FSGS, M Hattori
This (small )Japanese study demonstrated higher circulating anti-nephrin antibodies in patients with recurrent FSGS.
Exciting!!
#ERA23
@sarah_gleeson_
⚡NDT Digest⚡
Renal transplant surgery: important things a nephrologist should know
📸 Factors to consider in surgical assessment of potential renal transplant recipients
📖 Access full paper here:
#kidney
#transplant
#surgery
@stevo_1975
We are pleased to announce the latest Impact Factors for our official journals:
@CKJsocial
has received its first IF of 2.975 and
@NDTsocial
has achieved a latest IF of 4.198. Explore the most cited articles freely available until November 30, 2019.
💥CKJ Review💥
Recurrence of IgAN after kidney transplantation: incidence, risk factors, pathophysiology & management of immunosuppressive therapy
📸Schematic representation of IgAN recurrence in the graft & potential site of drug intervention
🆓 access:
🔆 Haemodiafiltration or haemodialysis for kidney failure: the totality of evidence based on individual patient data meta-analysis from randomised controlled trials
By Prof Robin WM Vernooij
Tweets by Sourabh Sharma
@iamnephrologist
#SoMe
#ERA24
⚡NDT Digest⚡
Nomenclature for renal replacement therapies in chronic patients
📸Extracorporeal circuits for the main hemodialysis therapies, with associated disposables/circuits and connector colours
📖
@NDTsocial
#RRT
#hemodialysis
💥To celebrate the 60 years of ERA, let's go over the best of ERA Journals!
🔍Check out one of the best CKJ articles👇
📌Challenges of defining renal response in ANCA-associated vasculitis: call to action?
#ERA60years
#BestOfCKJ
#ERA24
Clinical pearls from CKJ
@CKJsocial
by speaker
@KateIsabelle24
post by
@G_ErtanDemirtas
, social media team
1. First pearls, 🔎what about membranous nephropathy?
The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab
🔆HD & PD- Modality selection for the elderly
By Prof Mehmet Kanbay
💥Elderly May require early initiation
💥Proper geriatric assessment is needed
💥Individualisation is the key- Don’t ignore patient preference
#ERA24
@iamnephrologist
📣The May issue of NDT is now online!
👉Selected for you from May issue:
A plea for renin–angiotensin system blockers as first-line treatment in cases of severe acute hypertension
📸Treatment protocol for malignant hypertension